christophe willekens, md: reduced venetoclax and azacitidine in aml
Published 1 year ago • 1.2K plays • Length 9:42Download video MP4
Download video MP3
Similar videos
-
4:42
dr. willekens presents efficacy findings for reduced-dose venetoclax in aml
-
3:40
venetoclax plus hypomethylating agents leads to high response rates in older patients with aml
-
4:49
for older aml patients, venetoclax with low-dose cytarabine is safe and “promising”
-
1:22
venetoclax & azacitidine for aml in 2020
-
15:13
how effective is venetoclax? #aml
-
7:50
which aml patients benefit most from venetoclax treatment?
-
9:41
what is venetoclax? #aml
-
2:50
pevonedistat, venetoclax and azacitidine for older aml patients
-
6:23
venetoclax, clad/ldac and azacitdine in older aml patients
-
2:49
venetoclax and azacitidine for young patients with aml
-
3:10
venetoclax and azacitidine in newly diagnosed aml patients | dan pollyea, md, ms | ash 2022 #aml
-
1:40
pivekimab sunirine in combination with venetoclax and azacitidine for cd123-positive aml
-
1:08
the importance of predicting venetoclax response in patients with aml
-
4:59
venetoclax plus clad/ldac and aza for older aml patients
-
6:53
the efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve aml
-
5:36
venetoclax and azacitidine in mds patients
-
1:33
phase i trial results for oral azacitidine and venetoclax in r/r aml
-
2:19
cladribine ldac venetoclax alternated with azacitidine venetoclax in older patients with aml
-
2:43
venetoclax azacitidine in unfit patients with aml
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
2:53
venetoclax and magrolimab for treatment of aml and mds
-
1:57
venetoclax and azacitidine for aml ineligible for standard induction